Skip to main content

Table 1 Baseline characteristics of postmenopausal patients with major depressive disorder

From: Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study

Characteristics

Venlafaxine

(n = 82)

Fluoxetine

(n = 90)

P

Age (years), mean ± SD

56.7 ± 6.8

56.9 ± 5.8

0.83

BMI (kg/m2), mean ± SD

23.9 ± 3.8

23.0 ± 2.9

0.14

Age at onset (years), mean ± SD

52.3 ± 7.9

51.5 ± 8.2

0.55

Duration of illness (years), mean ± SD

5.7 ± 6.2

6.3 ± 6.9

0.54

Previous episodes, mean ± SD

2.0 ± 1.9

2.0 ± 2.3

0.88

HAMD-24 total score, mean ± SD

30.5 ± 7.3

31.7 ± 8.5

0.34

Anxiety/somatization score, mean ± SD

8.3 ± 2.6

8.8 ± 2.5

0.22

CGI-I score, mean ± SD

3.7 ± 1.2

3.7 ± 1.0

0.78

Family history, n (%)

10 (12.2)

9 (10.0)

0.65

  1. BMI body mass index, CGI-I Clinical Global Impression of Improvement, HAMD-24 24-item Hamilton Depression Rating Scale, SD standard deviation